Literature DB >> 19120076

Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.

S A Hoffman1, L Wang, C V Shah, V N Ahya, A Pochettino, K Olthoff, A Shaked, K Wille, V N Lama, A Milstone, L B Ware, J Orens, A Weinacker, E Demissie, S Bellamy, S M Kawut, W W Hancock, J D Christie.   

Abstract

Primary graft dysfunction (PGD) after lung transplantation causes significant morbidity and mortality. We aimed to determine the role of cytokines and chemokines in PGD. This is a multicenter case-control study of PGD in humans. A Luminex analysis was performed to determine plasma levels of 25 chemokines and cytokines before and at 6, 24, 48 and 72 h following allograft reperfusion in 25 cases (grade 3 PGD) and 25 controls (grade 0 PGD). Biomarker profiles were evaluated using a multivariable logistic regression and generalized estimating equations. PGD cases had higher levels of monocyte chemotactic protein-1 (MCP-1)/chemokine CC motif ligand 2 (CCL2) and interferon (IFN)-inducible protein (IP-10)/chemokine CXC motif ligand 10 (CXCL10) (both p < 0.05), suggesting recruitment of monocytes and effector T cells in PGD. In addition, PGD cases had lower levels of interleukin (IL-13) (p = 0.05) and higher levels of IL-2R (p = 0.05). Proinflammatory cytokines, including tumor necrosis factor (TNF)-alpha, and IFN-gamma decreased to very low levels after transplant in both PGD cases and controls, exhibiting no differences between the two groups. These findings were independent of clinical variables including diagnosis in multivariable analyses, but may be affected by cardiopulmonary bypass. Profound injury in clinical PGD is distinguished by the upregulation of selected chemokine pathways, which may useful for the prediction or early detection of PGD if confirmed in future studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120076      PMCID: PMC2821938          DOI: 10.1111/j.1600-6143.2008.02497.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  24 in total

Review 1.  Lung transplantation.

Authors:  S M Arcasoy; R M Kotloff
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods.

Authors:  Jason D Christie; Dirk Van Raemdonck; Marc de Perrot; Mark Barr; Shaf Keshavjee; Selim Arcasoy; Jonathan Orens
Journal:  J Heart Lung Transplant       Date:  2005-10       Impact factor: 10.247

Review 3.  Design issues in case-control studies.

Authors:  S Wacholder
Journal:  Stat Methods Med Res       Date:  1995-12       Impact factor: 3.021

4.  Impact of primary graft failure on outcomes following lung transplantation.

Authors:  Jason D Christie; Jeffrey S Sager; Stephen E Kimmel; Vivek N Ahya; Christina Gaughan; Nancy P Blumenthal; Robert M Kotloff
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

5.  The effect of primary graft dysfunction on survival after lung transplantation.

Authors:  Jason D Christie; Robert M Kotloff; Vivek N Ahya; Gregory Tino; Alberto Pochettino; Christina Gaughan; Ejigayehu DeMissie; Stephen E Kimmel
Journal:  Am J Respir Crit Care Med       Date:  2005-03-11       Impact factor: 21.405

Review 6.  The role of the chemokines in myocardial ischemia and reperfusion.

Authors:  Nikolaos G Frangogiannis
Journal:  Curr Vasc Pharmacol       Date:  2004-04       Impact factor: 2.719

7.  Clinical risk factors for primary graft failure following lung transplantation.

Authors:  Jason D Christie; Robert M Kotloff; Alberto Pochettino; Selim M Arcasoy; Bruce R Rosengard; J Richard Landis; Stephen E Kimmel
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

8.  Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury.

Authors:  Babu V Naidu; Alexander S Farivar; Steven M Woolley; David Grainger; Edward D Verrier; Michael S Mulligan
Journal:  J Heart Lung Transplant       Date:  2004-01       Impact factor: 10.247

9.  The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft.

Authors:  C Serrick; R Adoumie; A Giaid; H Shennib
Journal:  Transplantation       Date:  1994-12-15       Impact factor: 4.939

10.  Primary graft failure following lung transplantation.

Authors:  J D Christie; J E Bavaria; H I Palevsky; L Litzky; N P Blumenthal; L R Kaiser; R M Kotloff
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

View more
  45 in total

1.  CASE 7--2014 Rescue therapy with early extracorporeal membrane oxygenation for primary graft dysfunction after bilateral lung transplantation.

Authors:  Ali M Farooki; Heidi Bazick-Cuschieri; Emily K Gordon; James C Lee; Edward C Cantu; John G Augoustides
Journal:  J Cardiothorac Vasc Anesth       Date:  2013-08-30       Impact factor: 2.628

2.  Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation.

Authors:  Shahid Husain; Mariangela R Resende; Nimerta Rajwans; Ricardo Zamel; Joseph M Pilewski; Maria M Crespo; Lianne G Singer; Kenneth R McCurry; Jay K Kolls; Shaf Keshavjee; W Conrad Liles
Journal:  Transplantation       Date:  2014-01-15       Impact factor: 4.939

Review 3.  Selecting lung transplant candidates: where do current guidelines fall short?

Authors:  Jaime L Hook; David J Lederer
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

4.  Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation.

Authors:  Benjamin H Friedman; Joshua H Wolf; Liqing Wang; Mary E Putt; Abraham Shaked; Jason D Christie; Wayne W Hancock; Kim M Olthoff
Journal:  Liver Transpl       Date:  2012-02       Impact factor: 5.799

5.  Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.

Authors:  J M Diamond; D J Lederer; S M Kawut; J Lee; V N Ahya; S Bellamy; S M Palmer; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; P D Shah; A Weinacker; D Weill; B A Kohl; C C Deutschman; S Arcasoy; A S Shah; J A Belperio; D Wilkes; J M Reynolds; L B Ware; J D Christie
Journal:  Am J Transplant       Date:  2011-08-22       Impact factor: 8.086

6.  Noninvasive Imaging of CCR2+ Cells in Ischemia-Reperfusion Injury After Lung Transplantation.

Authors:  Y Liu; W Li; H P Luehmann; Y Zhao; L Detering; D H Sultan; H-M Hsiao; A S Krupnick; A E Gelman; C Combadiere; R J Gropler; S L Brody; D Kreisel
Journal:  Am J Transplant       Date:  2016-07-14       Impact factor: 8.086

7.  Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.

Authors:  R J Shah; N Wickersham; D J Lederer; S M Palmer; E Cantu; J M Diamond; S M Kawut; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; A Weinacker; P Shah; S Arcasoy; D S Wilkes; J D Christie; L B Ware
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

8.  Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.

Authors:  J M Diamond; S M Kawut; D J Lederer; V N Ahya; B Kohl; J Sonett; S M Palmer; M Crespo; K Wille; V N Lama; P D Shah; J Orens; S Bhorade; A Weinacker; E Demissie; S Bellamy; J D Christie; L B Ware
Journal:  Am J Transplant       Date:  2011-02-07       Impact factor: 8.086

9.  Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

Authors:  Rupal J Shah; Joshua M Diamond; Edward Cantu; James C Lee; David J Lederer; Vibha N Lama; Jonathan Orens; Ann Weinacker; David S Wilkes; Sangeeta Bhorade; Keith M Wille; Lorraine B Ware; Scott M Palmer; Maria Crespo; A Russell Localio; Ejigayehu Demissie; Steven M Kawut; Scarlett L Bellamy; Jason D Christie
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

10.  Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Authors:  Joshua M Diamond; Tatiana Akimova; Altaf Kazi; Rupal J Shah; Edward Cantu; Rui Feng; Matthew H Levine; Steven M Kawut; Nuala J Meyer; James C Lee; Wayne W Hancock; Richard Aplenc; Lorraine B Ware; Scott M Palmer; Sangeeta Bhorade; Vibha N Lama; Ann Weinacker; Jonathan Orens; Keith Wille; Maria Crespo; David J Lederer; Selim Arcasoy; Ejigayehu Demissie; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.